[{"id":"3c7531a5-d2c1-4a20-9990-f4c698763dbe","acronym":"SPARTA","url":"https://clinicaltrials.gov/study/NCT03175224","created_at":"2022-05-11T08:56:01.997Z","updated_at":"2024-07-02T16:35:04.401Z","phase":"Phase 2","brief_title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","source_id_and_acronym":"NCT03175224 - SPARTA","lead_sponsor":"Apollomics Inc.","biomarkers":" HGF • PTPRZ1","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion","tags":["HGF • PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101) • CBT101"],"overall_status":"Recruiting","enrollment":" Enrollment 497","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-10"},{"id":"5a3f91fc-1205-487d-92df-2b35d3f75bbe","acronym":"SHIELD-1","url":"https://clinicaltrials.gov/study/NCT03993873","created_at":"2021-01-18T19:38:12.132Z","updated_at":"2024-07-02T16:35:28.600Z","phase":"Phase 1/2","brief_title":"Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET","source_id_and_acronym":"NCT03993873 - SHIELD-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation • MET fusion","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elzovantinib (TPX-0022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 09/21/2019","start_date":" 09/21/2019","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2025","study_completion_date":" 03/02/2025","last_update_posted":"2023-11-20"},{"id":"e39da979-9b9b-423f-988a-e881ebd01029","acronym":"","url":"https://clinicaltrials.gov/study/NCT03088930","created_at":"2021-01-18T15:13:09.164Z","updated_at":"2024-07-02T16:36:17.241Z","phase":"Phase 2","brief_title":"Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03088930","lead_sponsor":"University of Colorado, Denver","biomarkers":" ALK • MET • ROS1","pipe":" | ","alterations":" ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • MET fusion","tags":["ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 12/13/2017","start_date":" 12/13/2017","primary_txt":" Primary completion: 01/13/2021","primary_completion_date":" 01/13/2021","study_txt":" Completion: 01/13/2021","study_completion_date":" 01/13/2021","last_update_posted":"2022-02-11"}]